Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo.
Chen B, Roy SG, McMonigle RJ, Keebaugh A, McCracken AN, Selwan E, Fransson R, Fallegger D, Huwiler A, Kleinman MT, Edinger AL, Hanessian S. Chen B, et al. Among authors: huwiler a. ACS Chem Biol. 2016 Feb 19;11(2):409-14. doi: 10.1021/acschembio.5b00761. Epub 2015 Dec 14. ACS Chem Biol. 2016. PMID: 26653336 Free PMC article.
Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Imeri F, Fallegger D, Zivkovic A, Schwalm S, Enzmann G, Blankenbach K, Meyer zu Heringdorf D, Homann T, Kleuser B, Pfeilschifter J, Engelhardt B, Stark H, Huwiler A. Imeri F, et al. Among authors: huwiler a. Neuropharmacology. 2014 Oct;85:314-27. doi: 10.1016/j.neuropharm.2014.05.012. Epub 2014 May 23. Neuropharmacology. 2014. PMID: 24863045
FTY720 and two novel butterfly derivatives exert a general anti-inflammatory potential by reducing immune cell adhesion to endothelial cells through activation of S1P(3) and phosphoinositide 3-kinase.
Imeri F, Blanchard O, Jenni A, Schwalm S, Wünsche C, Zivkovic A, Stark H, Pfeilschifter J, Huwiler A. Imeri F, et al. Among authors: huwiler a. Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1283-92. doi: 10.1007/s00210-015-1159-5. Epub 2015 Aug 13. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 26267293 Free article.
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
McCracken AN, McMonigle RJ, Tessier J, Fransson R, Perryman MS, Chen B, Keebaugh A, Selwan E, Barr SA, Kim SM, Roy SG, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider AJ, Clare S, Müschen M, Huwiler A, Kleinman MT, Hanessian S, Edinger AL. McCracken AN, et al. Among authors: huwiler a. Leukemia. 2017 Mar;31(3):669-677. doi: 10.1038/leu.2016.244. Epub 2016 Aug 30. Leukemia. 2017. PMID: 27573555 Free PMC article.
167 results